Tiger Brokers

Biophytis: Positive Post-HOC Analysis Of Phase 2-3 COVA Clinical Study

T-Reuters
Nov 03, 2022

Biophytis SA :Biophytis Reports Positive Post-Hoc Analysis Of The Phase 2-3 Cova Clinical Study Strongly Supporting Therapeutic Potential Of Sarconeos (Bio101) In Covid-19.A Reduction In Risk Of Early Death Or Respiratory Failure At Day 28 Of 45% In Intent-To-Treat (Itt) Population And 53% In Per Protocol (Pp) Population.A Reduction In Risk Of Death At Day 90 Of 43% In Itt Population And 70% In Pp Population.Start Of Regulatory Development Of Sarconeos (Bio101) Targeting Conditional And Emergency Use Marketing Authorisations In 2023.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10